Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | KRAS | P01116 | 4/20 | 0.49 |
| ▸ | HINT1 | P49773 | 1/20 | 0.49 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057089 | 0.94 | NT5E (0.61) | NT5EHPRT1TGM2KRASHINT1 | |
| SCHEMBL8897427 | 0.91 | NT5E (0.65) | NT5EHPRT1TGM2KRASHINT1 | |
| SCHEMBL12300422 | 0.87 | NT5E (0.56) | NT5EHPRT1TGM2KRASHINT1 | |
| SCHEMBL12300460 | 0.87 | NT5E (0.59) | NT5EHPRT1TGM2KRASHINT1 | |
| SCHEMBL12300425 | 0.86 | HPRT1 (0.55) | NT5EHPRT1TGM2KRASHINT1 | |
| SCHEMBL12300450 | 0.83 | HPRT1 (0.41) | NT5EHPRT1TGM2STING1PNP | |
| F-Arag SCHEMBL21465284 | 0.82 | NT5E (0.61) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL600735 | 0.81 | NT5E (0.70) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL26067722 | 0.81 | NT5E (0.70) | NT5ETGM2KRASHINT1FUT5 | |
| SCHEMBL21128179 | 0.81 | STING1 (0.48) | NT5ESTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | NT5E 203/4885HPRT1 106/4885TGM2 2160/4885 |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | NT5E 203/4885HPRT1 106/4885TGM2 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.